UCB/LIBD To Discover New Drugs For Cognitive Impairment

Espicom View: Although early stage, this is a typical example of the increasingly common pairing of large pharma with specialist research institutes to expedite the R&D process, populate waning pipelines and minimise internal R&D expenditure.

UCB and the Lieber Institute for Brain Development (LIBD) are entering a strategic collaboration for the discovery of new drug candidates for treating patients with cognitive impairment. UCB and the LIBD will jointly generate novel lead compounds and further optimise them starting from chemical compounds provided by both partners. The specific interdisciplinary structure of the LIBD is expected to bring to the collaboration its unique expertise in translating basic research and drug discovery into effective clinical proof-of-concept.

Financial details of the collaboration were not disclosed.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: United States, Belgium

Access all of our latest analysis, data and forecasts - request a trial